We enrolled 1116 persons with COPD whose forced expiratory volume in one second ( FEV1 ) was 30 to 90 percent of the predicted value in a 10-center , placebo-controlled , randomized trial of inhaled triamcinolone acetonide administered at a dose of 600 microg twice daily .
